Insmed Incorporated

INSM

US4576693075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:30:00 07/03/2026 am IST			5-day change	1st Jan Change
140.13 ^USD	-2.40%		-6.16%	-19.48%

02/03	Insmed Incorporated Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 09:50 AM
24/02	Insmed Insider Sold Shares Worth $1,615,257, According to a Recent SEC Filing	MT

Insmed Incorporated(NasdaqGS:INSM) dropped from Russell 2000 Growth Benchmark

Published on 06/30/2025

S&P Capital IQ

INSMED INCORPORATED

-2.40%

Insmed Incorporated(NasdaqGS:INSM) dropped from Russell 2000 Growth Benchmark

Latest news about Insmed Incorporated

02/03	Insmed Incorporated Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 09:50 AM
24/02	Insmed Insider Sold Shares Worth $1,615,257, According to a Recent SEC Filing	MT
23/02	Mizuho Securities Cuts Insmed Price Target to $204 From $211, Maintains Outperform Rating	MT
23/02	Insmed Gets UK Marketing Authorization for Non-Cystic Fibrosis Bronchiectasis Treatment	MT
23/02	MHRA says licensed brensocatib as first drug for non-cystic fibrosis bronchiectasis in patients aged 12+	RE
20/02	Insmed Q4 Reinforces Confidence in Brinsupri Growth, RBC Says	MT
20/02	Insmed May Top Revenue Target for Bronchiectasis Drug Brinsupri, Morgan Stanley Says	MT
20/02	Morgan Stanley Lifts Price Target on Insmed to $166 From $162, Keeps Equalweight Rating	MT
20/02	US Equity Indexes Fall as Trump Signals Timeline on Iran Diplomacy	MT
19/02	Insmed Incorporated, Q4 2025 Earnings Call, Feb 19, 2026
19/02	Insmed Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
19/02	The Market's Nerves Are Showing
19/02	Insmed reports fourth-quarter and full-year 2025 financial results and provides business update	RE
19/02	Insmed Q4 Loss Widens, Revenue Rises	MT
19/02	Earnings Flash (INSM) Insmed Incorporated Reports Q4 Revenue $263.8M, vs. FactSet Est of $237.8M	MT

Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

Employees

1,664

Sector

Biotechnology & Medical Research

More about the company